Cade approves pharmaceutical joint venture

Jornal DCI/SP | 01/29/2016
The Conselho Administrativo de Defesa Econômica (Cade) approved without constraints the joint venture between Pfizer and Orygen Biotecnologia, controlled by Biolab and Eurofarma, according to a procedural order published in Federal Official Gazette (DOU).

The joint venture will manufacture and commercialize in Brazil up to five biosimilars: adalimumab, bevacizumab, infliximab, rituximab or trastuzumab based biosimilar. According to the companies, the operation represents the reformulation of co-operation agreement signed on May 2014, approved by Cade in the same year. Orygen Biotecnologia is a joint venture between the economical groups Biolab and Eurofarma. 
 
Learn more
arrow_backward See more articles
Customer Service 0800 724 6522
faleconosco@biolabfarma.com.br
Be connected